Revenio: Springing to life
We expect the start of the year to still have been difficult for Revenio, with Q1 results below the strong comparison period, but a return to earnings growth thereafter. The valuation level is reasonable (2024e EV/EBIT 22x) relative to the outlook for the next few years, and the company is undervalued compared to its peer group. As a result, we consider the stock's risk/reward ratio to be reasonably good again.
Revenio Group
Revenio is a medical technology company. Within the Group, there is research and development of pressure measurement technology that is used in the treatment of a number of diseases such as glaucoma, osteoporosis, skin cancer, and asthma. Operations are held worldwide and are run via most subsidiaries, each with a business focus. The company's head office is located in Vantaa.
Read more on company pageKey Estimate Figures04.04
2023 | 24e | 25e | |
---|---|---|---|
Omsætning | 96,6 | 104,6 | 120,1 |
vækst-% | -0,45 % | 8,33 % | 14,80 % |
EBIT (adj.) | 28,5 | 30,4 | 37,9 |
EBIT-% (adj.) | 29,53 % | 29,09 % | 31,53 % |
EPS (adj.) | 0,80 | 0,88 | 1,12 |
Udbytte | 0,38 | 0,42 | 0,58 |
Udbytte % | 1,40 % | 1,45 % | 2,01 % |
P/E (adj.) | 33,95 | 33,10 | 26,06 |
EV/EBITDA | 23,75 | 22,56 | 17,81 |